Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03947749 · ClinicalTrials.gov registry record
Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain
A clinical trial, sponsored by University of Florida.
- Completed
- Registry status
- 275
- Enrollment target
NCT03947749: Completed study, sponsored by University of Florida.
NCT03947749 is a clinical trial that has completed, run by University of Florida. The registered enrollment target is 275 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03947749 has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- 275 participants
- Enrollment target
Study Summary
Genetic variability from epigenetic modification of genes related to pain physiology and opioid pharmacodynamics may influence susceptibility to high-impact chronic musculoskeletal pain, opioid efficacy, and vulnerability to opioid abuse. Exploring the role of epigenomics and opioid addiction may improve understanding and treatment of these complex multifactorial conditions and, potentially, reduce their development.
Primary Outcome
Symptom assessment tool measures six items on 5-point scales for pain interference on aspects of daily life. The higher the total score, the more severe the symptom.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2019-09-25 |
| Est. Completion | 2023-04-06 |
What the finished NCT03947749 record still lists
NCT03947749 is an observational study that tracks outcomes without assigning an intervention. The registered 275 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03947749 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03947749 about?
NCT03947749 is a clinical study titled "Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain". Genetic variability from epigenetic modification of genes related to pain physiology and opioid pharmacodynamics may influence susceptibility to high-impact chronic musculoskeletal pain, opioid efficacy, and vulnerability to opioid abuse. Exploring the role of epigenomics and opioid addiction may im...
What is the current status of trial NCT03947749?
This trial is currently completed. The enrollment target is 275 participants. The study started on 2019-09-25. Estimated completion is 2023-04-06.
Who is sponsoring clinical trial NCT03947749?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269190 · 275 participants · NA
Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery
- NCT01900132 · 275 participants · NA
Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers
- NCT04104776 · 275 participants · Phase 1
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- NCT04765150 · 275 participants
Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI